Advances in the study of acetaminophen-induced liver injury

Xinghui Li; Jiaqi Ni; Li Chen

doi:10.3389/fphar.2023.1239395

Advances in the study of acetaminophen-induced liver injury

Front Pharmacol. 2023 Aug 4:14:1239395. doi: 10.3389/fphar.2023.1239395. eCollection 2023.

Authors

Xinghui Li¹, Jiaqi Ni^{1

2

3}, Li Chen^{2

3}

Affiliations

¹ West China School of Pharmacy, Sichuan University, Chengdu, China.
² Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
³ Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China.

Abstract

Acetaminophen (APAP) overdose is a significant cause of drug-induced liver injury and acute liver failure. The diagnosis, screening, and management of APAP-induced liver injury (AILI) is challenging because of the complex mechanisms involved. Starting from the current studies on the mechanisms of AILI, this review focuses on novel findings in the field of diagnosis, screening, and management of AILI. It highlights the current issues that need to be addressed. This review is supposed to summarize the recent research progress and make recommendations for future research.

Keywords: acetaminophen-induced liver injury; diagnosis; drug-induced liver injury; prevention and management; screening.

Publication types

Review

Grants and funding

This work was supported by a grant from the Fundamental Research Funds for the Central Universities (YJ202339).